Fluzone High-Dose Quadrivalent Northern Hemisphere 49281-0226
Generic: Influenza A Virus A/victoria/4897/2022 Ivr-238 (h1n1) Antigen (formaldehyde Inactivated), Influenza A Virus A/croatia/10136rv/2023 X-425a (h3n2) Antigen (formaldehyde Inactivated), Influenza B Virus B/phuket/3073/2013 Antigen (formaldehyde Inactivated), And Influenza B Virus B/michigan/01/2021 Antigen (formaldehyde Inactivated)
Product NDC
49281-0226- Manufacturer
- Sanofi Pasteur Inc.
- Dosage Form
- Injection, Suspension
- Route
- Intramuscular
- Product Type
- Vaccine
- Marketing Start
- July 1, 2025
- Application
- BLA103914
Active Ingredients
| Ingredient | Strength |
|---|---|
| Influenza A Virus A/croatia/10136rv/2023 X-425a (h3n2) Antigen (formaldehyde Inactivated) | 60 ug/.7mL |
| Influenza A Virus A/victoria/4897/2022 Ivr-238 (h1n1) Antigen (formaldehyde Inactivated) | 60 ug/.7mL |
| Influenza B Virus B/michigan/01/2021 Antigen (formaldehyde Inactivated) | 60 ug/.7mL |
| Influenza B Virus B/phuket/3073/2013 Antigen (formaldehyde Inactivated) | 60 ug/.7mL |
Packaging Options(1)
10 SYRINGE, GLASS in 1 PACKAGE (49281-226-65) / .7 mL in 1 SYRINGE, GLASS (49281-226-88)
External Resources